Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacteroides thetaiotaomicron
- Development stage
- Phase 1
- Lead developer
- 4D pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Thetanix is the brand name for a single-strain, live biotherapeutic product (LBP) containing the bacterium *Bacteroides thetaiotaomicron*. [1, 5] It was developed by 4D Pharma for the treatment of Crohn's disease, particularly in pediatric and adolescent populations. [2, 4] As an LBP, its mechanism of action involves modulating the host's gut microbiome. Preclinical and clinical studies suggest it may reduce inflammation by antagonizing the NF-κB transcription factor, which in turn reduces pro-inflammatory cytokines like TNF-α. [1, 2, 5] Thetanix is administered as an oral, gastroresistant capsule. [2, 3] A Phase 1b clinical trial in adolescents with stable Crohn's disease found the treatment to be safe and well-tolerated. [1, 6]
- Brand names
- Thetanix
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)NF-κB
Beyond the preview
Go deeper on Bacteroides thetaiotaomicron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacteroides thetaiotaomicron.